Alcon “Hawk” AMD RTH-258-C001

Status: Ongoing, but not recruiting participants

ClinicalTrials.gov Identifier: NCT02307682

RTH-258-C001: A two-year, randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the efficacy and safety of RTH258 versus Aflibercept in subjects with Neovascular Age-Related Macular Degeneration.

Condition: Neovascular Age-Related Macular Degeneration

Study Type: Interventional

Duration: 96 Weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.